Navigation Links
AlphaMed Pharmaceuticals Announces Breakthrough in the Development of Recombinant Alpha 1-Antitrypsin
Date:3/7/2008

LARGO, Fla., March 7 /PRNewswire/ -- AlphaMed Pharmaceuticals Corporation announced today that the Company has successfully expressed a humanized version of the therapeutic protein alpha 1-antitrypsin (AAT). AlphaMed scientists expressed their recombinant AAT utilizing the Company's proprietary production system in yeast. The yeast has been genetically altered to produce a molecule "virtually identical" to that which is manufactured by the human body.

"This marks a major milestone for this company and AAT research," stated Joseph McGuirl, AlphaMed's CEO, "AlphaMed is the first company to develop an AAT molecule with glycosylation that resembles the human protein that is naturally secreted from the liver. The Company has begun to develop products to treat a variety of diseases including hereditary emphysema, COPD, asthma and cystic fibrosis." Joseph McGuirl joined AlphaMed in July, 2007 and is the former Head of Licensing and Development for Hoffmann-LaRoche.

"I am glad to confirm that the work progressed well so far," stated Dr. Roland Contreras Ph.D. of the VIB, University of Ghent located in Belgium who has been supervising AlphaMed's molecular biology. "The two complex sugars of the left arm have been added with good efficiency. This is an important milestone and in my opinion a glycoform worth purifying. It is a mammalian hybrid form."

Plasma-derived AAT is currently marketed by several companies for the treatment of hereditary emphysema and generates over $200 Million in revenues, annually. The plasma-derived AAT, however, is marked by shortages and blood contamination risks.

In addition, AAT plays a vital role in the inflammatory cascade and in many instances can act as a replacement for conventional steroids. Additional disease indications treatable by AAT therapy include atopic dermatitis, psoriasis, rheumatoid arthritis and others. "The market potential for AAT therapies is in the billions," stated McGuirl, "and given Alph
'/>"/>

SOURCE AlphaMed Pharmaceuticals Corporation
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related medicine technology :

1. Memory Pharmaceuticals Reports Fourth Quarter and Full Year 2007 Financial Results
2. Arriva Pharmaceuticals Moves Forward to Phase 2b Development of Lead Inhaled Protein rAAT Replacement Therapy for Hereditary Emphysema
3. NexGenix Pharmaceuticals Presents Data on a Novel Small Molecule Inhibitor of Heat Shock Protein 90 (Hsp90) at the GTCbio Cancer Drugs Research & Development Conference
4. ISTA Pharmaceuticals Announces Physician-Sponsored Clinical Study of Xibrom(TM) Combination Therapy with Lucentis(R)
5. Memory Pharmaceuticals & Roche Expand Development Program for MEM 3454 in Schizophrenia
6. Poniard Pharmaceuticals Announces Positive First-line Phase 1 Safety and Efficacy Data With Picoplatin in Metastatic Prostate Cancer Patients
7. Indevus Pharmaceuticals Provides Update on PRO 2000 Program
8. Keryx Biopharmaceuticals Completes SUN-MICRO Phase 3 Pivotal Trial
9. Lotus Pharmaceuticals, Inc. Achieves Significant Milestones in the Development of Isosorbide Mononitrate Sustained Release Tablets
10. Tigris Pharmaceuticals Initiates Phase I Study of AFP-464 in Patients with Solid Tumors
11. Peregrine Pharmaceuticals Opens Enrollment in Phase II Clinical Trial of Bavituximab in Patients with Advanced Breast Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/20/2008)...wswire/ -- Milk. It does a body good. And,now it,...ter years of,research, scientists at OncoNutritio...k that stimulate the body,s own production of anti... Release, go to:, http://www.prnewswire.com/mnr/eq...w cancer therapies, the chief scientist, Dr. David...
(Date:11/20/2008)...swire/ -- Radius Health ("Radius") announced today...ts second institutional financing round, increasin...he total amount raised since the company,s incepti...nvestors participated in the financing, led by MPM...al, The Wellcome Trust, HealthCare Ventures, Oxfor...
(Date:11/20/2008)... The Scandinavian-based drug,devel...ts of studies on its,lead antimicrobial candidate...he studies showed that the novel lytic peptidomime...ificantly better towards killing Staphylococcus,a...d standard drugs. In,addition to this it has prov...
(Date:11/19/2008)...e statistical significance , , ISELIN, N.J....ration (Nasdaq: PARS ) today announced results f...oEmulsion (NE) drug delivery technology formulated... multi-center, randomized, double-blinded, placebo...y of the Company,s 3% Diclofenac Diethanolamine Na...
Breaking Medicine Technology:Photos: Peptides Discovered to Alleviate Chemotherapy Side Effects 2Radius Raises Additional $15 Million, Increasing Second Private Equity Financing Round to $82.5 Million 2Lytix Presents LTX-109 Anti-Microbial Data at ICAAC 2Pharmos Announces Clinical Results from Phase 2a Trial of Topical Diclofenac NanoEmulsion Cream 2Experimental Drug Fights Prostate Cancer 5747 1Experimental Drug Fights Prostate Cancer 5747 2Tweens double use of diabetes drugs 5745 1Tweens double use of diabetes drugs 5745 2Higher levels of pollutants found in fish caught near a coal fired power plant 5743 1Higher levels of pollutants found in fish caught near a coal fired power plant 5743 2HCA Reports Third Quarter 2007 Results 5741 1HCA Reports Third Quarter 2007 Results 5741 2HCA Reports Third Quarter 2007 Results 5741 3HCA Reports Third Quarter 2007 Results 5741 4HCA Reports Third Quarter 2007 Results 5741 5HCA Reports Third Quarter 2007 Results 5741 6HCA Reports Third Quarter 2007 Results 5741 7HCA Reports Third Quarter 2007 Results 5741 8HCA Reports Third Quarter 2007 Results 5741 9HCA Reports Third Quarter 2007 Results 5741 10HCA Reports Third Quarter 2007 Results 5741 11HCA Reports Third Quarter 2007 Results 5741 12HCA Reports Third Quarter 2007 Results 5741 13HCA Reports Third Quarter 2007 Results 5741 14
...NESS WIRE)--Mar 20, 2007 - Arrowhead,Research Corp...y-owned subsidiary Calando Pharmaceuticals has pub...Academy of Sciences,(PNAS) of the first non-human ...h Calando,s lead siRNA therapeutic candidate., Cal...eted,polymeric delivery systems and siRNA design t...
...20, 2007 /PRNewswire/ -- Treatment of,coronary art... the,inpatient setting, according to a study publi..., U.S. hospitalization rates for heart attacks (ac...from 2002 to 2005, possibly due,to broader use of ...irin, as well as declines in risk factors like smo...
Other Medicine Technology:Arrowhead Subsidiary, Calando Pharmaceuticals Publishes Study on,Targeted, Systemic Delivery of siRNA 2Arrowhead Subsidiary, Calando Pharmaceuticals Publishes Study on,Targeted, Systemic Delivery of siRNA 3Hospitalization Rates for Coronary Artery Disease Decline in the,U.S. 2Hospitalization Rates for Coronary Artery Disease Decline in the,U.S. 3
(Date:11/21/2008)...archers remain cautious about future antibiotic re...Y, Nov. 21 (HealthDay News) -- People with moderat...(COPD) may be able to reduce the frequency of exac...antibiotic, a new report says. , The study, pu...erican Journal of Respiratory and Critical Care Me...
(Date:11/21/2008)... Nov. 21 The Universit...e beginning of a collaborative effort to eradicate...or Breast Cancer Awareness and Research of the Ame... Lady of the United States, and Vivian Fernandez d...oining M. D. Anderson in the initiative are the U....
(Date:11/21/2008)...areholders Intend To Vigorously Protect Investment...TI, Nov. 21 Dr. Stephen...n amendment to their Schedule 13D with the U.S. Se...ously filed a 13D disclosing ownership of 11.4% of...s 77 LasikPlus fixed-site laser vision correction ...
(Date:11/21/2008)... LAKES, N.J., Nov. 21 To...edical intervention in treating 88 percent of pati... of Americans treated for a chronic condition acco...ng and 75 percent of all medical costs. A proprie... by Medco Health Solutions, Inc. (NYSE: MHS ) si...
Breaking Medicine News(10 mins):Health News:Long-Term Erythromycin Cut COPD Complications 2Health News:First Lady Laura Bush's Partnership for Breast Cancer Awareness and Research Extends to Panama 2Health News:First Lady Laura Bush's Partnership for Breast Cancer Awareness and Research Extends to Panama 3Health News:Founders & Former Executive Management Team of LCA-Vision Seek Change to Rescue Company 2Health News:Founders & Former Executive Management Team of LCA-Vision Seek Change to Rescue Company 3Health News:Founders & Former Executive Management Team of LCA-Vision Seek Change to Rescue Company 4Health News:Founders & Former Executive Management Team of LCA-Vision Seek Change to Rescue Company 5Health News:Founders & Former Executive Management Team of LCA-Vision Seek Change to Rescue Company 6Health News:Founders & Former Executive Management Team of LCA-Vision Seek Change to Rescue Company 7Health News:New Data: Advanced Pharmacy Model Significantly Reduces Gaps in Care for Patients with Chronic and Complex Conditions; Improves Clinical and Financial Outcomes 2Health News:New Data: Advanced Pharmacy Model Significantly Reduces Gaps in Care for Patients with Chronic and Complex Conditions; Improves Clinical and Financial Outcomes 3Health News:New Data: Advanced Pharmacy Model Significantly Reduces Gaps in Care for Patients with Chronic and Complex Conditions; Improves Clinical and Financial Outcomes 4Health News:New Data: Advanced Pharmacy Model Significantly Reduces Gaps in Care for Patients with Chronic and Complex Conditions; Improves Clinical and Financial Outcomes 5Health News:New Data: Advanced Pharmacy Model Significantly Reduces Gaps in Care for Patients with Chronic and Complex Conditions; Improves Clinical and Financial Outcomes 6
...-Sinai Medical Center this week launched an Intern...duct both adult and embryonic stem cell research. ...arrival of renowned Israeli developmental genetici...the institute’s co-director along with David I. Me...
... temperatures have been on an all time high in the...keeping tabs on the rising temperature and polluti...during the period from 15th to 19th July, the temp...ong with nitrogen dioxide pollution, which is know...
...nt investigation reveals that vocal cord dysfuncti... M. Weinberger, of the University of Iowa,// and h...s who were reported to be suffering from this dysf...patients, 41 were reported to be suffering from as...
... 40 percent of female German smokers refuse to qui...tive study by the Instituts Gewis for the Hamburg-...ed, 39 percent of those between ages 25 and 39 rep...n weight." Experts disagree. Most smokers do gain...
Other Medicine News:Health News:Center Launches New International Stem Cell Research Institute 2Health News:Sensor Images Show Soaring Temperature and Pollution Levels in UK 2
CleanBox DNA workstation with two 254nm UV lambs & 12-hr timer, 90cm (36-inch)width, single door, 115V (w/crating)
...ing of tube racks. Its camera-based vision system ... per rack, making it ideal for use in automated se... rack to be read automatically and can be easily a...prevents a rack from being read in the wrong orien...
Polypropylene workbench top with powder-coated steel legs. Height is adjustable from 25"-34". Available in hundreds of sizes and configurations. Accessories include shelves, drawers, light fixtures a
Perforated or Rod Top, Free Standing or Wall Mounted, Storage Cubby Optional, Polypropylene Construction
Medicine Products: